|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Ovarian Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma | |||||
| Ovarian Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Adnexal Diseases | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Gonadal Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Ovarian Diseases | |||||
| Urogenital Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| Cetuximab | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| ImClone Systems | |||||
| Bristol-Myers Squibb | |||||